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Participants with the gene expansion for Huntington disease (HD) but not yet diagnosed
were evaluated annually. Unidimensional diagnosis (UD) was a motor diagnosis defined as
a diagnostic confidence level (DCL) of 4 (unequivocal motor signs, ≥99% confidence) on
the standardized motor exam of the Unified Huntington Disease Rating Scale (UHDRS).
Multidimensional diagnosis (MD) was defined as answering yes on Question 80 (Q80)
of the UHDRS, ≥99% confidence of manifest HD based on the entire UHDRS. Motor,
cognitive, and behavioral measures of phenotype at first diagnosis were compared
by t-tests between participants diagnosed via motor exam (UD) and those diagnosed
via multidimensional input (MD). Cluster analysis identified clusters based on UHDRS
domains.186 participants received a diagnosis of HD during a maximum of 6.4 years
of follow-up. In 108 (58.1%) the diagnosis by MD and UD occurred simultaneously,
while in 69 (37.1%) the diagnosis by MD occurred prior to UD. Participants who were
diagnosed by MD prior to UD were less impaired on motor (12.2 ± 6.7 vs. 22.4 ± 9.3,
p < 0.0001), and cognitive (290.7 ± 56.2 vs. 258.0 ± 53.7, p = 0.0002), but not behavioral
measures (16.3 ± 21.2 vs. 18.6 ± 22.1, p = 0.49) when compared with those diagnosed
simultaneously. Cluster analysis identified three clusters that represented primarily
cognitively impaired, behaviorally impaired, and cognitively preserved phenotypes. A
multidimensional method results in an earlier diagnosis with less motor and cognitive
impairment than a motor diagnosis. Findings have implications for designing preventive
trials and providing clinical care in prodromal HD.
Keywords: Huntington’s disease, trinucleotide repeat diseases, cohort studies, natural history studies, outcome
research
INTRODUCTION
Huntington disease (HD) is an adult-onset, autosomal dominant,
progressive, and fatal neurodegenerative disease characterized by
the clinical triad of a movement disorder, cognitive decline, and
behavioral disturbances caused by a cytosine-adenine-guanine
(CAG) repeat in the 5′-translated region of the gene on the short
arm of chromosome 4 (Duyao et al., 1993). The precise point of
disease diagnosis is poorly characterized, with clinical abnormal-
ities emerging gradually over many years during a “pre-manifest”
Abbreviations: AD, Alzheimer disease; CAG, cytosine-adenine-guanine;
DCL, diagnostic confidence level; HD, Huntington disease; PREDICT-HD,
Neurobiological Predictors of Huntington’s Disease; Q80, Question 80; SDM, sym-
bol digit modalities; TFC, Total Functional Capacity; UHDRS, Unified Huntington
Disease Rating Scale.
or prodromal phase (Huntington Study Group, 2006; Paulsen
et al., 2006).
A challenge of therapeutic research is in the identification of
treatments that impact the manifestation of disease in individuals
at varying stages of disease progression. For the neurodegenera-
tive diseases, much effort has been devoted to early identification
and staging using clinical outcome measures or biomarkers. For
instance, there are widespread efforts to detect “mild cogni-
tive impairment” prior to dementia so that therapeutics might
be considered before extensive cell death has occurred. Even in
HD, in which a cohort can be identified years prior to diagno-
sis, challenges remain in designing trials aimed at delaying ill-
ness progression. The Neurobiological Predictors of Huntington’s
Disease (PREDICT-HD) study is a longitudinal prospective eval-
uation in individuals at risk for HD with known gene status.
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The PREDICT-HD study should help identify outcomes for use in
trials aimed at delaying the manifestation of illness in prodromal
HD. However, in order to show that an intervention can delay dis-
ease, there needs to be consensus on how to best define the clinical
diagnosis of HD. The traditional method of HD diagnosis rests on
the motor manifestation of disease though the cognitive and psy-
chiatric aspects of HD have been recognized for decades. Efforts
towardmore refined disease stagingmay be improved with amore
comprehensive consideration ofHD. Therefore, we compared two
methods of diagnosis in the PREDICT-HD cohort: a multidimen-
sional diagnosis (MD) and a unidimensional diagnosis (UD) or
motor diagnosis.
MATERIALS AND METHODS
All aspects of the study were approved by the Institutional Review
Board at each participating institution. Participants signed con-
sents for participation and to release their de-identified data for
analyses.
OVERVIEW OF PREDICT-HD
The PREDICT-HD study is designed to prospectively characterize
refined clinical, neurobiological, and neurobehavioral markers of
HD prior to the point of traditional motor diagnosis in a pop-
ulation known to carry the HD CAG expansion (Paulsen et al.,
2006). Participants at risk for HD were recruited from 32 sites
in the United States, Canada, Australia, and Europe beginning in
2001. All participants were required to have voluntarily under-
gone genetic testing for the HD CAG expansion independent
from the study. Participants were evaluated annually with stan-
dardized assessments ofmotor, cognition, behavior, function, and
clinical diagnosis.
Only individuals with the HD CAG expansion and without
manifest disease (prodromal HD) as defined by the absence of
unequivocal motor signs (diagnostic confidence level of less than
4 on question 17 of the UHDRS, Table 1A) on their initial exam-
ination were included in the current analysis. Control subjects
Table 1 | The Unified Huntington Disease Rating Scale diagnostic
confidence level and Q80 diagnostic criteria.
A. Diagnostic confidence level
To what degree are you confident that this person meets the
operational definition of the unequivocal presence of an otherwise
unexplained extrapyramidal movement disorder (e.g., chorea,
dystonia, bradykinesia, rigidity) in a subject at risk for HD?
0 = normal (no abnormalities)
1 = non-specific motor abnormalities (less than 50% confidence)
2 = motor abnormalities that may be signs of HD (50–89% confidence)
3 = motor abnormalities that are likely signs of HD (90–98% confidence)
4 = motor abnormalities that are unequivocal signs of HD
(≥99% confidence)
B. Q80 diagnostic criteria
Based on the entire UHDRS (Motor, Cognitive, Behavioral, and
Functional components) do you believe with a confidence level ≥99%
that this participant has manifest HD? (0 = No, 1 = Yes)
were those participants who had tested negative for the HD CAG
expansion and had participated in at least two visits. For purposes
of this analysis, the last visit in controls was used for comparison
with cases.
CLINICAL ASSESSMENTS
Huntington disease clinical diagnosis
Motor Diagnosis: The Huntington Disease Rating Scale
(UHDRS) diagnostic confidence level (DCL) is the standard
measure used for clinical diagnosis in at-risk individuals and
is based solely on the motor evaluation. It is a categorical scale
(Table 1A) with a range from 0 (normal) to 4 (unequivocal signs
of HD, ≥99% confidence ≥ on the part of the examiner). The
DCL has previously shown fair inter-rater reliability (weighted
kappa = 0.67, SE = 0.09) (Hogarth et al., 2005). Participants
had a clinical diagnosis of HD at the time of the first rating of a
DCL = 4.
Multidimensional Diagnosis: Question 80 (Q80) of the
UHDRS asks raters to take into account all aspects of the UHDRS
(motor, cognitive, behavioral, and functional) and tomake a deci-
sion (yes or no) whether a subject has a diagnosis of HD with a
confidence level 99% (Table 1B). The first occurrence of Q80 =
yes was the multidimensional diagnostic criteria used for the
current analyses.
The primary analysis compared participants who were diag-
nosed by MD prior to receiving a diagnosis by UD with partici-
pants who received a diagnosis of MD and UD simultaneously. A
small proportion of individuals received a diagnosis by UD prior
to MD and these participants were not included in the analysis.
UNIFIED HUNTINGTON DISEASE RATING SCALE OUTCOMES
The current analyses focused solely on the UHDRS assessments,
since UD is rated on the motor UHDRS only and MD specifically
asks raters to make a determination based on the entirety of the
Hungtington Study Group (1996). The motor UHDRS assessed
for the presence and severity of motor features (Hungtington
Study Group, 1996). The motor UHDRS is a standardized assess-
ment consisting of 31 items rated on a scale from 0 to 4 with
a score of 0 indicating no abnormalities and 4 indicating the
most severe impairment. The maximum possible total score is
124. Previously motor scores have been shown to distinguish con-
trols from prodromal HD cases and subtle motor abnormalities
were associated with closer estimated diagnosis of disease (Biglan
et al., 2009). In manifest HD, oculomotor, rigidity, chorea, dysto-
nia, and bradykinesia domains have been identified and were used
to clarify if specific motor features were associated with specific
clusters at time of clinical diagnosis (Marder et al., 2000).
The cognitive section of the UHDRS includes verbal fluency,
symbol digit modalities test, and Stroop word, color, and interfer-
ence tests (Hungtington Study Group, 1996; Biglan et al., 2009).
Each of these cognitive tests has been shown to distinguish gene
mutation carriers from controls in prodromal HD (Paulsen et al.,
2008; Stout et al., 2011). Total cognitive scores are calculated
by summing the five individual scores in the UHDRS cognitive
domain.
The behavioral section of the UHDRS consists of 11 items eval-
uating various behavioral signs and symptoms. Individuals are
Frontiers in Aging Neuroscience www.frontiersin.org April 2013 | Volume 5 | Article 12 | 2
Biglan et al. Refining HD diagnosis
ranked on both severity and frequency on a 0 to 4 scale with 0
being not present and 4 being severe and frequent (Hungtington
Study Group, 1996). Total behavioral scores are calculated by
summing the severity and frequency items and ranges from 0 (no
behavioral symptoms) to 88 (most severe behavioral symptoms).
The functional section of the UHDRS includes the Functional
Assessment Scale, Independence Scale, and the Total Functional
Capacity (TFC) (Hungtington Study Group, 1996). The TFC
is a standard assessment of overall function in HD and has a
demonstrated reliability for indexing progression in various diag-
nosed HD populations (Marder et al., 2000; Huntington Study
Group, 2001). The TFC rates individuals’ function on the follow-
ing domains: occupation, handling finances, domestic chores, and
activities of daily living. The TFC ranges from 13 (normal func-
tion) to 0 (complete loss of function). In prodromal HD, there is
a strong tendency for participants to have the maximum score,
as most have normal function; thus the TFC was treated as a
dichotomous variable (TFC < 13) to indicate whether an indi-
vidual has some kind of impairment in functionality for daily
living (Paulsen et al., 2010). For assessment of employment status
UHDRS item #43 (ability to work at accustomed employment)
and item #44 (ability to work at any employment) were used.
STATISTICAL ANALYSIS
Kaplan-Meier curves were generated to describe the probability
of being diagnosis-free over time and to evaluate the tempo-
ral relationship between incident diagnoses using the different
diagnostic criteria.
UHDRS total motor, total cognitive, and total behavioral
scores at the time of incident diagnosis were compared between
the different diagnostic groups using t-tests.
Chi-square tests were used to compare differences in the fre-
quency of diagnosis by the same vs. different raters between the
different diagnostic groups.
To evaluate the factors associated with diagnosis in those par-
ticipants who received a diagnosis of MD prior to UD, K-mean
clustering with the pseudo-F statistic criterion was performed to
identify categories of participants (clusters) at the time of diag-
nosis. The UHDRS total motor score, total cognitive score, and
total behavior score at diagnosis were used in the cluster analy-
sis. In order to ascertain if raters utilized participants’ functional
status in the diagnostic decision, TFC, and employment status
were compared across the clusters. To determine if specific motor
features were associated with different clusters, the sum of each
motor domain was compared across clusters. The ANOVA, Fisher
Exact Tests, or Kruskall-Wallis Test were performed as appropriate
to determine the difference between the clusters and the control
group and post-hoc pairwise comparisons using t-tests or chi-
square tests, corrected for multiple comparisons (alpha < 0.01)
to determine the statistical ordering among the groups.
RESULTS
Since 2001, a total of 1054 individuals have been enrolled in the
PREDICT-HD study. Of these participants, 821 (78%) carried the
CAG expansion and were considered prodromal (DCL < 4) at
baseline. A total of 233 (22%) of the participants enrolled did not
carry the CAG expansion (controls); of these, 194 had at least two
follow-up visits.
Over a mean follow-up of 3.1 years (SD = 1.4 years and
range= 6.4 years) a total of 186 CAG expanded participants (23%
of total CAG expanded) received a first diagnosis of manifest HD
by either diagnostic criteria (MD or UD). Of these diagnosed
individuals, 108 (58.1%) received a diagnosis by UD and MD
simultaneously, 69 (37.1%) by MD prior to UD, and 9 (4.8%)
by UD prior to MD. Figure 1 shows the Kaplan-Meier estimates
of the diagnosis-free probability curves over 6 years of follow-up
for diagnosis based on the UD and MD criteria.
Of those diagnosed, 148 (79.6%) had the same rater, whereas
38 (20.4%) had different raters for UD and MD. DCL = 4 and
Q80 diagnoses were more likely to occur simultaneously when the
rater was the same (89.8%). Q80 diagnosis also preceded DCL =
4 diagnosis more often when the rater was the same (73.9%)
(Table 2).
Table 3 demonstrates the clinical features at the time of diag-
nosis by the different criteria. Participants who were diagnosed
by MD prior to UD were less impaired on UHDRS total motor
scores (12.2 ± 6.7 vs. 22.4 ± 9.3, p < 0.0001) and on total cogni-
tive scores (290.7 ± 56.2 vs. 258.0 ± 53.7, p = 0.0002) compared
with individuals who received the diagnoses simultaneously.
FIGURE 1 | Kaplan-Meier estimate of the probability of being
diagnosis-free during follow-up by type of diagnosis (UHDRS Q80 =
yes and UHDRS DCL = 4).
Table 2 | Diagnostic agreement between by same vs. different
raters∗,†.
Diagnosis Same rater Different rater Total
Simultaneous Q80/DCL = 4 97 (89.8%) 11 (10.2%) 108
Q80 before DCL = 4 51 (73.9%) 18 (26.1%) 69
Total 148 (83.6%) 29 (16.4%) 177
*p = 0.005 for the comparison of clinical diagnosis by rater category.
†Does not include the 9 participants where DCL = 4 occurred before Q80.
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There was no statistical difference on UHDRS behavioral scores
(16.3 ± 21.2 vs. 18.6 ± 22.1, p = 0.49) between the two groups.
A cluster analysis using K-mean clustering in the partici-
pants that received MD prior to UD was performed and a three
cluster solution was identified based on the pseudo-F statistic
criterion. Table 4 shows the mean total motor, cognitive, and
behavioral scores by clusters and controls. Cluster 1 identifies a
predominantly cognitively impaired phenotype because it had the
lowest UHDRS cognitive mean, but the second highest behavior
mean and the highest total motor mean (Cluster 1 might also
be labeled as predominantly cognitive/motor). Cluster 2 identi-
fies a predominantly behaviorally impaired phenotype as it had
the highest behavior mean, but had the second highest cognitive
mean and the lowest total motor mean among the gene-expanded
participants. Cluster 3 represents a cognitively preserved group
because the cluster had the highest cognitive mean (even higher
than controls), the lowest behavior mean, and the second high-
est total motor mean among gene-expanded participants. All
clusters had significantly worse motor scores compared with
controls. A more detailed assessment of motor features using
the motor sub-domains (Table 4) suggests that cluster 3 (cogni-
tively preserved) had the most chorea while cluster 1 (cognitively
impaired) performed the worst on the bradykinesia domain. A
cluster analysis of the participants that received simultaneous
diagnoses identified a three-cluster solution that was qualitatively
similar (i.e., cognitive, behavioral, and preserved phenotypes),
except that participants performed worse on motor and cognitive
measures than the same clusters in participants with MD prior
to UD (results not shown). All three clusters were more likely
than controls to have greater functional impairment as measured
Table 3 | Clinical features at time of diagnosis.
Variables Q80 before DCL = 4 (n = 69) Simultaneous Q80/DCL = 4 (n = 108) Controls† (n = 194) p-value*
Gender (%F) 65.7 66.7 66.0 0.89
Age (mean ± SD) 46.3 ± 9.2 46.7 ± 10.3 46.7 ± 11.1 0.81
CAG (mean ± SD) 43.1 ± 3.1 43.5 ± 3.1 20.1 ± 3.5 0.43
UHDRS motor (mean ± SD) 12.2 ± 6.7 22.4 ± 9.3 2.8 ± 3.1 <0.001
UHDRS cognition (mean ± SD) 290.5 ± 56.5 258.0 ± 53.7 341.4 ± 47.4 <0.001
UHDRS behavior (mean ± SD) 16.3 ± 21.2 18.6 ± 22.1 5.7 ± 9.3 0.49
UHDRS TFC (%<13) 31.9 48.1 7.0 0.03
*p-values are for the comparison between Q80 diagnosis before DCL = 4 and simultaneous diagnosis.
†The values of controls were taken at the last visit.
Table 4 | Group comparisons between clusters.
Variables Control Cluster 1 Cluster 2 Cluster 3 ANOVA Pair-wise comparisons (alpha 0.01)
(n = 194) (n = 21) (n = 32) (n = 15) p-value
Age
(mean ± SD) 46.75 ± 11.13 45.70 ± 9.32 47.26 ± 9.97 44.70 ± 7.70 0.85 –
CAG
(mean ± SD) 20.12 ± 3.45 43.58 ± 2.59 43.22 ± 3.66 42.73 ± 2.09 <0.001 Control < C1, C2, C3
UHDRS
Total motor
(mean ± SD) 2.75 ± 3.08 16.52 ± 5.60 9.56 ± 6.03 11.86 ± 6.78 <0.001 Control < C2, C3 < C1
Motor domains
Oculo (mean ± SD) 0.65 ± 1.23 4.52 ± 2.36 2.34 ± 2.89 3.57 ± 3.06 <0.001 Control < C2 < C1; Control < C3
Brady (mean ± SD) 1.44 ± 1.91 6.67 ± 3.12 4.03 ± 3.10 3.79 ± 2.81 <0.001 Control < C2, C3 < C1
Rigidity (mean ± SD) 0.31 ± 0.68 0.67 ± 1.15 0.53 ± 0.72 0.92 ± 1.07 0.004 Control < C3
Dystonia (mean ± SD) 0.06 ± 0.34 1.05 ± 1.56 0.38 ± 0.87 0.43 ± 0.76 <0.001 Control < C2 < C1; C3 < C1
Chorea (mean ± SD) 0.29 ± 0.69 3.62 ± 2.52 2.28 ± 2.05 3.14 ± 2.28 <0.001 Control < C1, C3; C2 < C1
Cognition
(mean ± SD) 341.4 ± 47.4 224.0 ± 25.7 303.8 ± 19.4 361.8 ± 22.6 <0.001 C1 < C2 < Control, C3
Behavior
(mean ± SD) 5.69 ± 9.29 12.65 ± 18.63 20.25 ± 21.28 7.47 ± 10.05 <0.001 Control, C3 < C2
Cluster 1, predominantly cognitive; Cluster 2, predominantly behavioral; Cluster 3, cognitively preserved.
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by TFC. Whereas participants in cluster 3 were more likely to
be employable compared to the other clusters, this did not meet
the threshold for significance and all clusters were less likely
to be employable compared with controls (see Supplementary
Table e-1).
There was no statistical difference between the clusters in the
proportion of raters that were the same vs. raters who were
different (see Supplementary Table e-2).
DISCUSSION
In participants with prodromalHD enrolled in the PREDICT-HD
study, a multidimensional diagnosis occurs earlier and with less
motor and cognitive impairment than a diagnosis based on the
motor examination. Given the results of our analysis, a diagno-
sis that considers cognitive and behavioral features in addition to
motor features has face validity. Therefore, compared to the tra-
ditional motor diagnosis, a multidimensional diagnosis may be a
preferable outcome for use in future trials aimed at delaying the
manifestation of HD.
The current analysis also identified different phenotypes
in HD at the time of diagnosis: predominantly cognitively
impaired (with motor impairments), predominantly behaviorally
impaired, and cognitively preserved. These phenotypic clusters
had motor impairments greater than controls at diagnosis despite
marked differences among the clusters in cognitive and behav-
ioral performance. Thus, while the traditional motor diagnosis
selects for the identification of a predominantly motor pheno-
type, a multidimensional diagnosis may identify predominantly
non-motor presentations.
It is unclear why certain participants were given a multidi-
mensional diagnosis in the absence of significant impairment in
cognition or behavior in cluster 3 (cognitively preserved). This
was not related to worse functional performance in this group.
It may be that worse chorea in this group influenced raters to
make a diagnosis even when the overall motor impairment was
not deemed sufficient to make a motor diagnosis; or this could
reflect differences in how raters diagnose HD. In the future it may
be useful to ask raters what factors influenced their diagnostic
decision. It may also be beneficial to establish objective methods
for diagnosis, such as the establishment of certain cut-off scores
on the UHDRS.
Despite these findings, even individuals receiving a multi-
dimensional diagnosis are being identified relatively late after
the accumulation of significant clinical signs. PREDICT-HD and
other studies suggest that striatal atrophy and clinical features
may develop decades prior to diagnosis (Aylward et al., 2000;
Thieben et al., 2002; Paulsen et al., 2008). Recently, Sperling
et al. published recommendations from the National Institute
for Aging and the Alzheimer’s Association Working Group for
the research diagnosis of preclinical Alzheimer disease (AD)
(Sperling et al., 2011). They proposed a staged diagnosis for
preclinical AD with the earliest stage being associated with
biomarkers of AD pathophysiology (A-beta on PET or in CSF),
followed by biomarker evidence of neuronal injury (atrophy on
MRI) and finally the presence of subtle clinical signs that did
not meet criteria for mild cognitive impairment (Albert et al.,
2011). Using a similar strategy in prodromal HD, many CAG
expanded individuals at the time of enrollment in PREDICT-HD
already had evidence of subtle motor, cognitive, and behav-
ioral features and would have fallen into the last preclinical
stage using the AD model (Solomon et al., 2007; Beglinger
et al., 2008; Biglan et al., 2009; Duff et al., 2010; Stout et al.,
2011).
While HD does not yet have the same breadth of valid and
specific biomarkers as the AD research community, the iden-
tification of a similar staged categorization of prodromal HD
could be considered using neuroimaging biomarkers. Thus in
stage 1, CAG expanded individuals would have no evidence
of neuronal injury using volumetric MRI imaging or clinical
signs of HD on examination; in stage 2, there would be evi-
dence of neuronal injury as suggested by striatal atrophy on
volumetric MRI but no clinical signs of HD; finally in stage
3, individuals would have subtle clinical signs but would not
yet meet criteria for diagnosis. Ultimately, clinical trials aimed
at delaying manifestation in prodromal HD could evaluate the
impact of interventions on the progression through the pro-
posed stages, changes in volumetric imaging variables, changes
in clinical measures and finally the impact on a multidimensional
diagnosis of HD.
The current analysis has many limitations and caveats.
Foremost is the use of different raters for the motor and multi-
dimensional diagnoses. This introduced bias with a higher like-
lihood of discrepant diagnoses when the raters were different.
However, different raters were relatively Uncommon (see
Table 2), and there was no difference in rater type amongst the
three phenotypic clusters identified. Future studies using multi-
dimensional diagnosis should either have the rater making the
diagnostic rating complete all the appropriate assessments or, if
multiple individuals are doing the assessments, the multidimen-
sional diagnosis should be based on consensus after reviewing all
the data.
Another limitation was that raters were not specifically trained
on how to answer Q80. Differences in the timing of diagnosis
and the observed clinical phenotypes may relate to differences in
how raters make the assessment of a multidimensional diagnosis.
Some raters may be comfortable with diagnosing HD based on
the combination of subtle motor, cognitive, and behavioral signs,
whereas others may put more weight solely on the motor exam.
Future studies utilizing a multidimensional diagnosis will have to
standardize this decision process.
The significance of a clinical diagnosis is unclear. Striatal atro-
phy and subtle clinical features develop decades before traditional
diagnosis. In addition, while subjects at diagnosis were more
functionally impaired compared with controls, most individu-
als continued to work full-time and have minimal functional
impairment by the measures used in this study even at the time
of diagnosis. It remains to be seen whether regulatory bodies
will consider a delay in diagnosis as sufficient to show that an
intervention is effective or whether it will be necessary to show
a slowing in functional decline. If the latter proves to be true,
more refined measures of function in prodromal HD will be
necessary.
Finally, it is important to emphasize that the proposed diag-
nostic criteria is for research purposes only and not necessarily
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for the clinical diagnosis of patients. The decision to render a
clinical diagnosis in individuals at risk for HD is a complicated
one based on clinical features of disease, patient preferences, and
a detailed understanding of relevant psychosocial factors. The
potential clinical and emotional impact on patients and their
families of diagnosing individuals earlier and with less motor
impairment remains unknown.
A multidimensional diagnosis occurs earlier and with less
motor and cognitive impairment than the traditional motor
diagnosis and identifies clinical phenotypes that may have pre-
dominant non-motor features. A staging system in prodromal
HD, similar to that proposed in AD, may be of value. A better
understanding of diagnostic decision makingmay allow for better
standardization of diagnosis, and the development of clear crite-
ria for research and clinical diagnoses that may be utilized as an
outcome measure in future trials aimed at delaying diagnosis in
prodromal HD.
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